IDEAYA Biosciences, Inc.
IDYA
$19.13
$0.552.96%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -70.07% | -83.30% | -73.51% | -67.33% | -54.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -70.07% | -83.30% | -73.51% | -67.33% | -54.09% |
| Cost of Revenue | 127.53% | 67.40% | 63.09% | 47.79% | 44.64% |
| Gross Profit | -171.07% | -105.88% | -167.65% | -156.42% | -174.89% |
| SG&A Expenses | 38.84% | 31.22% | 30.02% | 24.50% | 18.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 111.62% | 60.54% | 56.52% | 43.16% | 39.13% |
| Operating Income | -143.23% | -88.94% | -125.77% | -113.47% | -115.08% |
| Income Before Tax | -142.98% | -72.59% | -107.33% | -88.77% | -92.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -142.98% | -72.59% | -107.33% | -88.77% | -92.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -142.98% | -72.59% | -107.33% | -88.77% | -92.59% |
| EBIT | -143.23% | -88.94% | -125.77% | -113.47% | -115.08% |
| EBITDA | -145.98% | -90.74% | -129.12% | -116.58% | -118.46% |
| EPS Basic | -67.97% | -19.54% | -50.67% | -31.49% | -40.58% |
| Normalized Basic EPS | -66.50% | -27.69% | -61.26% | -41.74% | -51.68% |
| EPS Diluted | -67.97% | -19.54% | -50.66% | -31.48% | -40.57% |
| Normalized Diluted EPS | -66.50% | -27.69% | -61.19% | -41.68% | -51.61% |
| Average Basic Shares Outstanding | 42.08% | 43.13% | 44.16% | 46.24% | 38.74% |
| Average Diluted Shares Outstanding | 42.08% | 43.13% | 43.56% | 45.57% | 38.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
